New biologic JLM019 enters human testing for advanced cancers

NCT ID NCT07623850

Recruiting now Disease control Sponsor: Jecho Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right dose, and see how the body handles it. About 115 participants will take part across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JLM019 injection (a biologic drug given intravenously)
What this could lead to: If this early trial shows JLM019 is safe and tolerable, it could pave the way for a new treatment option for advanced cancers and lymphomas.
What could go wrong: This is a very early Phase 1 study with only 115 participants, so it is primarily testing safety, not effectiveness. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR (PHASE 1) HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.